Table 2.
Prevalence ratios for aTRH associated with estimated GFR (eGFR) and albumin-to-creatinine ratio (ACR) among REGARDS study participants
| Characteristic | n | Crude Prevalence Ratio (95% CI) | Age-, Race-, and Sex-Adjusted Prevalence Ratio (95% CI) | Multivariable-Adjusteda Prevalence Ratio (95% CI) |
|---|---|---|---|---|
| eGFR, ml/min per 1.73 m2 | ||||
| ≥60 | 8876 | 1 (ref) | 1 (ref) | 1 (ref) |
| 45–59 | 1166 | 1.57 (1.41 to 1.76) | 1.49 (1.33 to 1.67) | 1.25 (1.11 to 1.41) |
| <45 | 658 | 2.12 (1.88 to 2.38) | 1.90 (1.68 to 2.15) | 1.20 (1.04 to 1.37) |
| ACR, mg/g | ||||
| <10 | 6166 | 1 (ref) | 1 (ref) | 1 (ref) |
| 10–29 | 2580 | 1.72 (1.55 to 1.90) | 1.68 (1.52 to 1.86) | 1.54 (1.39 to 1.71) |
| 30–299 | 1536 | 2.29 (2.06 to 2.54) | 2.09 (1.88 to 2.33) | 1.76 (1.57 to 1.97) |
| ≥300 | 418 | 3.99 (3.54 to 4.50) | 3.48 (3.08 to 3.93) | 2.44 (2.12 to 2.81) |
CI, confidence interval.
a
Adjusted for age, race, sex, geographic region, income, education, physical activity, current smoking, alcohol use, waist circumference, diabetes, total cholesterol, HDL cholesterol, statin use, C-reactive protein, history of myocardial infarction, history of stroke, ACR (log transformed in eGFR analyses), and eGFR (in ACR analyses).